Tags

Type your tag names separated by a space and hit enter

The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.
Curr Neurol Neurosci Rep. 2018 02 13; 18(2):8.CN

Abstract

PURPOSE OF REVIEW

Pharmaceutical cannabinoids such as nabiximols, nabilone and dronabinol, and plant-based cannabinoids have been investigated for their therapeutic potential in treating multiple sclerosis (MS) symptoms. This review of reviews aimed to synthesise findings from high quality systematic reviews that examined the safety and effectiveness of cannabinoids in multiple sclerosis. We examined the outcomes of disability and disability progression, pain, spasticity, bladder function, tremor/ataxia, quality of life and adverse effects.

RECENT FINDINGS

We identified 11 eligible systematic reviews providing data from 32 studies, including 10 moderate to high quality RCTs. Five reviews concluded that there was sufficient evidence that cannabinoids may be effective for symptoms of pain and/or spasticity in MS. Few reviews reported conclusions for other symptoms. Recent high quality reviews find cannabinoids may have modest effects in MS for pain or spasticity. Future research should include studies with non-cannabinoid comparators; this is an important gap in the evidence.

Authors+Show Affiliations

National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney, NSW, 2052, Australia. suzanne.nielsen@unsw.edu.au.National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney, NSW, 2052, Australia.National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney, NSW, 2052, Australia. Centre for Youth Substance Abuse Research, The University of Queensland, Royal Brisbane and Women's Hospital Brisbane, Brisbane, QLD, 4006, Australia.School of Medical Sciences, The University of Sydney, Sydney, NSW, 2006, Australia.National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney, NSW, 2052, Australia.Centre for Youth Substance Abuse Research, The University of Queensland, Royal Brisbane and Women's Hospital Brisbane, Brisbane, QLD, 4006, Australia.School of Medical Sciences, The University of Sydney, Sydney, NSW, 2006, Australia.National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney, NSW, 2052, Australia.

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

29442178

Citation

Nielsen, Suzanne, et al. "The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews." Current Neurology and Neuroscience Reports, vol. 18, no. 2, 2018, p. 8.
Nielsen S, Germanos R, Weier M, et al. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Curr Neurol Neurosci Rep. 2018;18(2):8.
Nielsen, S., Germanos, R., Weier, M., Pollard, J., Degenhardt, L., Hall, W., Buckley, N., & Farrell, M. (2018). The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Current Neurology and Neuroscience Reports, 18(2), 8. https://doi.org/10.1007/s11910-018-0814-x
Nielsen S, et al. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Curr Neurol Neurosci Rep. 2018 02 13;18(2):8. PubMed PMID: 29442178.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. AU - Nielsen,Suzanne, AU - Germanos,Rada, AU - Weier,Megan, AU - Pollard,John, AU - Degenhardt,Louisa, AU - Hall,Wayne, AU - Buckley,Nicholas, AU - Farrell,Michael, Y1 - 2018/02/13/ PY - 2018/2/15/entrez PY - 2018/2/15/pubmed PY - 2019/6/1/medline KW - Cannabinoid KW - Cannabis KW - Dronabinol KW - Multiple sclerosis KW - Nabiximols KW - Pain KW - Spasticity SP - 8 EP - 8 JF - Current neurology and neuroscience reports JO - Curr Neurol Neurosci Rep VL - 18 IS - 2 N2 - PURPOSE OF REVIEW: Pharmaceutical cannabinoids such as nabiximols, nabilone and dronabinol, and plant-based cannabinoids have been investigated for their therapeutic potential in treating multiple sclerosis (MS) symptoms. This review of reviews aimed to synthesise findings from high quality systematic reviews that examined the safety and effectiveness of cannabinoids in multiple sclerosis. We examined the outcomes of disability and disability progression, pain, spasticity, bladder function, tremor/ataxia, quality of life and adverse effects. RECENT FINDINGS: We identified 11 eligible systematic reviews providing data from 32 studies, including 10 moderate to high quality RCTs. Five reviews concluded that there was sufficient evidence that cannabinoids may be effective for symptoms of pain and/or spasticity in MS. Few reviews reported conclusions for other symptoms. Recent high quality reviews find cannabinoids may have modest effects in MS for pain or spasticity. Future research should include studies with non-cannabinoid comparators; this is an important gap in the evidence. SN - 1534-6293 UR - https://www.unboundmedicine.com/medline/citation/29442178/The_Use_of_Cannabis_and_Cannabinoids_in_Treating_Symptoms_of_Multiple_Sclerosis:_a_Systematic_Review_of_Reviews_ L2 - https://dx.doi.org/10.1007/s11910-018-0814-x DB - PRIME DP - Unbound Medicine ER -